ML239 ( —— )

产品货号. M17266 CAS No. 1378872-36-6

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

产品询价大包装询价加入购物车

产品名称

ML239
注意事项

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
产品简述

ML239 是一种有效的选择性乳腺癌干细胞抑制剂，IC50 为 1.16 μM。
产品描述

ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.
体外实验

ML239 (Compound 7j) is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM, with ～24-fold selectivity against the control cell line. ML239 inhibits breast cancer stem-like cells, most likely through activation of fatty acid desaturase 2 (FADS2). ML239 is cytotoxic to NCIH661 cells, and FADS2 knockdown reduces ML239 cytotoxicity, and furthermore, FADS2 inhibitor SC-26196 also reduces ML239 cytotoxicity in cancer cell lines (CCLs).
体内实验

——
同义词

——
通路

PI3K/Akt/mTOR signaling
靶点

mTOR
受体

Others
研究领域

Cancer
适应症

——

1.Germain AR,etal.Identification of a selective small molecule inhibitor of breast cancer stem cells.Bioorg Med Chem Lett. 2012 May 15;22(10):3571-4.

计算器

产品手册

关联产品

MHY1485

MHY1485 是一种 mTOR 激活剂；通过抑制自噬体和溶酶体之间的融合来抑制自噬过程，从而导致 LC3II 蛋白的积累和自噬体的增大。
mTOR inhibitor 9b

mTOR inhibitor 9b is an enzyme inhibitor of protein kinase mTOR he phosphatidylinositol 3-kinase PIK3CA with IC50s of 0.76 nm and 1.262 μM, respectively.mTOR inhibitor 9b possesses anticancer activity and can be used to study leukemia, skin, breast, lung and colon cancers.
MHY-1685

MHY-1685 是一种哺乳动物雷帕霉素靶点 (mTOR) 抑制剂和衰老抑制剂，可通过调节自噬使衰老 hCSC 恢复活力。